Table 2.
Demographics, clinical features, and laboratory indexes
| Characteristics | LTBI group n = 68) | Non-LTBI group (n = 164) | P |
|---|---|---|---|
| Before T-SPOT.TB assay | |||
| Age (years), mean ± SD | 38 ± 14 | 37 ± 14 | 0.268 |
| Male, n (%) | 39 (57.4) | 84 (51.2) | 0.411 |
| BD duration (years), mean ± SD | 10 ± 9 | 8 ± 7 | 0.087 |
| Oral ulcers, mean ± SD | |||
| Frequency (times/month) | 2.6 ± 1.7 | 1.9 ± 1.2 | 0.038 |
| Number | 4.5 ± 2 | 3 ± 1.5 | <0.001 |
| Scope of involvement | 3.3 ± 1 | 2.4 ± 1.1 | <0.001 |
| Genital ulcers, n (%) | 63 (92.6) | 109 (66.5) | 0.002 |
| Erythema nodosum, n (%) | 37 (54.4) | 74 (45.1) | 0.367 |
| Pseudofolliculitis, n (%) | 24 (35.3) | 47 (28.7) | 0.495 |
| Gastrointestinal ulcers, n (%) | 16 (23.5) | 22 (13.4) | 0.193 |
| Eye involvement, n (%) | 22 (32.3) | 20 (12.2) | 0.006 |
| Arthritis, n (%) | 22 (32.3) | 47 (28.7) | 0.609 |
| Vascular involvement, n (%) | 3 (4.4) | 7 (4.3) | 0.672 |
| CNS involvement, n (%) | 2 (2.9) | 4 (2.4) | 0.501 |
| TNF-α inhibitor | 8 (11.8) | 56 (34.1) | 0.001 |
| Leukocytes (×109) | 7.5 ± 2.5 | 6.9 ± 2.5 | 0.246 |
| Hemoglobin (g/L) | 136 ± 15 | 136 ± 18 | 0.907 |
| Blood platelets (×109) | 239 ± 89 | 228 ± 81 | 0.560 |
| Erythrocyte sedimentation rate (mm/h) | 27 ± 25 | 29 ± 26 | 0.672 |
| C-reactive protein (mg/L) | 14.8 ± 11 | 14.7 ± 12.6 | 0.990 |
| Immunoglobulin G (g/L) | 11.11 ± 3.55 | 10.86 ± 4.10 | 0.761 |
| Immunoglobulin A (g/L) | 2.42 ± 1.18 | 2.74 ± 1.19 | 0.302 |
| Immunoglobulin M (g/L) | 1.32 ± 0.61 | 1.37 ± 1.05 | 0.839 |
| Immunoglobulin E (IU/mL) | 55 ± 48 | 75 ± 58 | 0.458 |
| After T-SPOT.TB assay | |||
| AST (U/L) | 16.15 ± 7.17 | 16.38 ± 7.77 | 0.653 |
| ALT (U/L) | 17.97 ± 11.52 | 19.71 ± 13.73 | 0.483 |
| eGFR (mL/min/1.73 m2) | 115.53 ± 27.85 | 123.09 ± 31.25 | 0.094 |
| Rifampin, n (%) | 37 (54.4) | 0 (0) | <0.001 |
BD, Behçet’s disease; LTBI, latent tuberculosis infection; CNS, central nervous system; AST, aspartate transaminase; ALT, alanine transaminase; eGFR, estimated glomerular filtration rate.